Ignite Creation Date:
2024-05-06 @ 12:20 AM
Last Modification Date:
2024-10-26 @ 10:48 AM
Study NCT ID:
NCT01558947
Status:
UNKNOWN
Last Update Posted:
2012-03-20
First Post:
2012-03-07
Brief Title:
Peri-operative Chemotherapy With ECX or XP in the Treatment of Advanced Gastric Cancer
Sponsor:
Zhejiang Cancer Hospital
Organization:
Zhejiang Cancer Hospital
Study Overview
Official Title:
Peri-operative Chemotherapy With ECX Epirubicin Cisplatin Capecitabine or XP Capecitabine Cisplatin in the Treatment of Advanced Gastric Cancer a Randomized Multicenter Parallel Control
Status:
UNKNOWN
Status Verified Date:
2012-03
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to evaluate the safety and the effect of perioperative chemotherapy in the treatment of advanced gastric cancer
Detailed Description:
To evaluate the security and the relapse-free survival timerate123 yrs of perioperative chemotherapy with ECX epirubicin cisplatin capecitabine and XP capecitabine cisplatinin advanced gastric cancer
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None